Proteinsimple

Proteinsimple, a subsidiary of Bio-Techne Corporation based in San Jose, California, manufactures and sells specialized protein analysis instruments and consumables to the federal government as a prime contractor on a full-and-open basis, with no set-aside designations across its portfolio. The vendor operates as a for-profit manufacturer with a federal contracting footprint spanning 316 awards since 2009, predominantly in research-grade analytical instrumentation and maintenance services for biomedical agencies.

Proteinsimple's capability portfolio centers on capillary electrophoresis systems (JESS, Maurice, Peggy Sue, Ella platforms), single-cell dispensing equipment (Namocell Pala), and immunoassay platforms (SimplePlex), along with associated consumables, service plans, and maintenance contracts. Representative work includes a $141,485 purchase order from the Department of Agriculture (Plains Area) for NBAF Proteinsimple instruments (JESS and Maurice units) with delivery to Manhattan, Kansas and completion through September 2028; a $169,303 USDA award for a capillary electrophoresis system (Maurice OBM) with installation and training; a $156,050 Veterans Affairs award for a Namocell Pala Single Cell Dispenser supporting traumatic brain injury research; and recurring service plan awards from the National Institutes of Health for maintenance of installed systems, including $139,145 for a Platinum Service Plan supporting COVID-19 research at the National Institute of Allergy and Infectious Diseases running through June 2027.

Customer concentration is heavily skewed toward Department of Health and Human Services agencies and subordinate institutes. The top five federal customers account for approximately 34% of recent awards by count and 31% of combined potential value. The National Cancer Institute leads with 35 awards ($1 million combined potential value), followed by the National Institute of Allergy and Infectious Diseases (24 awards, $943 thousand), the Food and Drug Administration (19 awards, $873 thousand), the National Institute on Drug Abuse (14 awards, $489 thousand), and the National Institute of Child Health and Human Development (17 awards, $479 thousand). The Department of Veterans Affairs and Department of Agriculture also recur across the portfolio with equipment purchases and maintenance contracts. This concentration reflects Proteinsimple's position as a specialized biomedical research equipment supplier to civilian health agencies rather than defense or broader civilian procurement.

Activity has contracted sharply over the past five years. Award volume peaked at 22 awards in 2023, fell to 14 in 2024, and dropped to 5 in 2025 and 3 in 2026 (through September). Combined potential value across all 316 awards stands at $12.2 million, with $11.7 million (96%) obligated. The recompete cliff window shows six awards with ultimate completion dates in the next twenty-four months carrying combined potential value of $515 thousand — modest recompete exposure but reflecting the overall decline in acquisition pace. The vendor operates no parent contract vehicles (GWACs, BPAs, IDIQs) in the source data; all work flows through individual purchase orders on a transaction basis.

Work is distributed across product lines aligned to NAICS 541380 (Analytical Laboratory Instrument Manufacturing — 238 of 316 awards) and NAICS 811212 (Electronic and Precision Equipment Repair and Maintenance — 40 awards), with PSC codes split between Laboratory Equipment and Supplies (162 awards) and maintenance and repair (66 awards). Proteinsimple holds a single subcontract position as of the source date: a sub-award from General Dynamics Information Technology for bioeffects research products on the Bioeffects Research of Direct Radiation Energy Exposure (BRDEE) program, dated January 2, 2025. The parent company, Bio-Techne Corporation, operates additional subsidiaries (Brightwell Technologies Inc., Alpha Innotech Corp., Alpha Innotech Corporation) that may carry separate federal footprints not fully reflected in the Proteinsimple entity summary. Bio-Techne itself holds both federal prime contract and grant awards, suggesting the corporate group maintains diversified life sciences market access across instruments, assays, and reagent supply.